The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1290
Varenicline (Chantix) Warnings: Risk Versus Benefit
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The nicotine receptor partial agonist varenicline (Chantix – Pfizer) appears to be the most effective drug available to treat tobacco dependence,1 but the FDA has added a warning to the package insert about neuropsychiatric symptoms and exacerbations of preexisting psychiatric illness associated with its use. Agitation, hostility, depressed mood, suicidal ideation and suicidal behavior have been reported as postmarketing adverse events in patients who took varenicline and stopped smoking and in those who took the drug and continued to smoke.

MENTAL DISORDERS IN SMOKERS — Smoking itself is associated with psychiatric disease.2-4 Psychiatric symptoms including suicidal ideation and completed suicide have been associated both with smoking and with smoking cessation. A dose-response relationship has been described between smoking and suicide.5 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Varenicline (Chantix) Warnings: Risk Versus Benefit
Article code: 1290a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian